1. Tryptophan residues in TDP-43 and SOD1 modulate the cross-seeding and toxicity of SOD1.
- Author
-
Pokrishevsky E, DuVal MG, McAlary L, Louadi S, Pozzi S, Roman A, Plotkin SS, Dijkstra A, Julien JP, Allison WT, and Cashman NR
- Subjects
- Humans, Animals, Protein Folding, Motor Neurons metabolism, Motor Neurons pathology, Tryptophan metabolism, Zebrafish, Superoxide Dismutase-1 metabolism, Superoxide Dismutase-1 genetics, Superoxide Dismutase-1 chemistry, DNA-Binding Proteins metabolism, DNA-Binding Proteins genetics, Amyotrophic Lateral Sclerosis metabolism, Amyotrophic Lateral Sclerosis genetics, Amyotrophic Lateral Sclerosis pathology
- Abstract
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease of motor neurons. Neuronal superoxide dismutase-1 (SOD1) inclusion bodies are characteristic of familial ALS with SOD1 mutations, while a hallmark of sporadic ALS is inclusions containing aggregated WT TAR DNA-binding protein 43 (TDP-43). We show here that co-expression of mutant or WT TDP-43 with SOD1 leads to misfolding of endogenous SOD1 and aggregation of SOD1 reporter protein SOD1
G85R -GFP in human cell cultures and promotes synergistic axonopathy in zebrafish. Intriguingly, this pathological interaction is modulated by natively solvent-exposed tryptophans in SOD1 (tryptophan-32) and TDP-43 RNA-recognition motif RRM1 (tryptophan-172), in concert with natively sequestered TDP-43 N-terminal domain tryptophan-68. TDP-43 RRM1 intrabodies reduce WT SOD1 misfolding in human cell cultures, via blocking tryptophan-172. Tryptophan-68 becomes antibody-accessible in aggregated TDP-43 in sporadic ALS motor neurons and cell culture. 5-fluorouridine inhibits TDP-43-induced G85R-GFP SOD1 aggregation in human cell cultures and ameliorates axonopathy in zebrafish, via its interaction with SOD1 tryptophan-32. Collectively, our results establish a novel and potentially druggable tryptophan-mediated mechanism whereby two principal ALS disease effector proteins might directly interact in disease., Competing Interests: Conflict of interest J.-P. J. and S. P. are the owners of a patent US 15/532,909 titled “TDP-43-binding polypeptides useful for the treatment of neurodegenerative diseases”. J.-P. J. is the chief scientific officer of Imstar Therapeutics. The 3H1 misfolded SOD1 antibody used in this manuscript is owned by the University of British Columbia and licensed by ProMIS Neurosciences. N. R. C. is the Chief Scientific Officer of ProMIS Neurosciences. S. S. P. and N. R. C. have received consultation compensation from ProMIS and possess ProMIS stock and stock options. All other authors declare that they have no conflicts of interest with the contents of this article., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF